Genmab A/S (NASDAQ:GMAB) Shares Sold by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC reduced its stake in shares of Genmab A/S (NASDAQ:GMAB) by 5.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 214,472 shares of the company’s stock after selling 13,487 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Genmab A/S were worth $4,476,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Two Sigma Advisers LP lifted its holdings in shares of Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after acquiring an additional 280,900 shares during the period. FMR LLC lifted its holdings in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after acquiring an additional 33,076 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in shares of Genmab A/S by 6.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock worth $5,662,000 after acquiring an additional 14,165 shares during the period. Natixis Advisors LLC lifted its holdings in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after acquiring an additional 47,437 shares during the period. Finally, ABC Arbitrage SA purchased a new position in shares of Genmab A/S during the 4th quarter worth about $3,692,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Down 0.4 %

Shares of NASDAQ:GMAB opened at $22.34 on Monday. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The company has a 50 day moving average of $20.72 and a two-hundred day moving average of $22.89. The company has a market capitalization of $14.78 billion, a price-to-earnings ratio of 12.84, a price-to-earnings-growth ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several recent analyst reports. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.